Summary
Signal counts
Assets tracked: 3
Watchlist assets: 2
Registry stop assets: 0
Sponsor overview
Qilu Hospital of Shandong University
Public clinical-program risk signals across linked oncology Phase 2 assets for this sponsor.
Evidence links
Public sources
https://clinicaltrials.gov/study/NCT03750916 | https://clinicaltrials.gov/study/NCT06000033 | https://clinicaltrials.gov/study/NCT07201675
Assets
Linked programs
- Anlotinib Hydrochloride plus Docetaxel: Timeline Staleness Signal (4/5)
- Disitamab Vedotin+Anlotinib: Timeline Staleness Signal (4/5)
- RC48-ADC combined with toripalimab for bladder-sparing therapy: Low Signal (0/5)